Global Gabapentin Market
Global Gabapentin Market Set to Reach $3.07 Billion by 2030, Driven by Rising Usage for Neuropathic Pain and Epilepsy Treatment
09 août 2023 08h08 HE | Research and Markets
Dublin, Aug. 09, 2023 (GLOBE NEWSWIRE) -- The "Gabapentin Market Size, Share & Trends Analysis Report By Dosage Form (Tablet, Capsule, Oral Solution), By Type (Generic, Branded), By Application,...
Gabapentin Market Size to Hit USD 3.7 Billion by 2032 at 5.90% CAGR – Report by Market Research Future (MRFR)
11 juil. 2023 08h12 HE | Market Research Future
New York, USA, July 11, 2023 (GLOBE NEWSWIRE) -- Gabapentin Market Overview According to a Comprehensive Research Report by Market Research Future (MRFR), “Gabapentin Market Information By...
Global Gabapentin Market Report 2023: Increasing Utilization of Gabapentin in Various Conditions Fuels the Sector
02 mai 2023 11h38 HE | Research and Markets
Dublin, May 02, 2023 (GLOBE NEWSWIRE) -- The "Global Gabapentin Market Size, Share & Industry Trends Analysis Report by Application, Dosage Form, Distribution Channel, Regional Outlook and...
Multiple System Atrophy (MSA) - Market Insight, Epidemiology And Market Forecast 2023-2032
05 avr. 2023 06h03 HE | Research and Markets
Dublin, April 05, 2023 (GLOBE NEWSWIRE) -- The "Multiple System Atrophy (MSA) - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to's offering. ...
IRB Logo.png
Global Gabapentin Market [2022-2027] | COVID-19 Impact with Top Manufacturers Analysis (Novartis, TEVA, Mylan, Pfizer, etc) | Industry Size-Share, Demand-Supply Scenario, Emerging Trends, Production, Opportunities and Challenges
24 mars 2022 06h55 HE | Industry Research
Pune, March 24, 2022 (GLOBE NEWSWIRE) -- "Final Report will add the analysis of the impact of COVID-19 on this industry." Global “Gabapentin Market” Research Report 2022-2027 is a historical...
Ambrosia Announces G
Ambrosia Announces Groundbreaking MAT Study
19 mars 2018 13h30 HE | Ambrosia Treatment Center
West Palm Beach, FL, March 19, 2018 (GLOBE NEWSWIRE) -- For the first time, a groundbreaking new study is going to be conducted at a national treatment center. Ambrosia Treatment Center announced...
AXIM Biotech Enters Services Agreement With Israel-Based CRO to Begin Clinical POC Study on CBD and Gabapentin Chewing Gum for Treatment of Restless Leg Syndrome
20 juil. 2017 09h00 HE | AXIM Biotechnologies, Inc
NEW YORK, July 20, 2017 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a...